欢迎您访问中乔新舟官网!400-038-9959我的购物车(0)
您当前的位置:首页 > 产品中心
HOS人骨肉瘤细胞(STR鉴定)
英文名:HOS
货号:ZQ0952
价格:¥1400.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

HOS人骨肉瘤细胞(STR鉴定)

¥1400.00
+

HOS人骨肉瘤细胞专用培养基

¥350.00 ¥480.00

配套完培,省时省力,单买细胞无优惠

=

细胞套餐惊爆价

¥1750 ¥1880.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

HOS人骨肉瘤细胞

货号

ZQ0952

产品介绍

HOS是一种人骨肉瘤细胞系,源自一位13岁白人女性的骨肉瘤组织。js rhim从人骨肉瘤中获得HOS。这种细胞系具有低饱和密度和低克隆效率,对化合物和病毒转化敏感。HOS细胞适用于3D细胞培养,以其侵袭性生长和对治疗的抵抗性而闻名,被广泛应用于研究骨肉瘤的发病机制、治疗方法以及新药的开发。

种属

性别/年龄

/13岁

组织

骨;骨头

疾病

骨肉瘤

细胞类型

肿瘤细胞

形态学

混合的成纤维细胞和上皮样细胞

生长方式

贴壁

倍增时间

~36 hours (PubMed=21519327)

培养基和添加剂

MEM(含NEAA)(中乔新舟  货号:ZQ-300+10%FBS(中乔新舟  货号:ZQ500-A+1%PS(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0952

生物安全等级

BSL-1

STR位点信息

Amelogenin: X

CSF1PO: 12

D13S317: 12

D16S539: 10,13

D5S818: 13

D7S820: 11,12

THO1: 6

TPOX: 8,11

vWA: 18

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

 ***

基因表达

 ***

保藏机构

ATCC; CRL-1543 BCRC; 60308 BCRJ; 0339 

供应限制

仅供科研使用

货号

ZQ0952

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


论文标题: Exosomal MiR-199a-5p Inhibits Tumorigenesis and Angiogenesis by Targeting VEGFA in Osteosarcoma
DOI: 10.3389/fonc.2022.884559
发表时间: 2022-05-16
期刊: Frontiers in Oncology
影响因子: 5.738
货号: ZQ0952
产品名称: HOS cells

原文链接: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148962/



PubMed=6954533; DOI=10.1073/pnas.79.7.2194
Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F.
Differential expression of the amv gene in human hematopoietic cells.
Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982)


PubMed=2823272; DOI=10.1073/pnas.84.21.7716
Masuda H., Miller C., Koeffler H.P., Battifora H.A., Cline M.J.
Rearrangement of the p53 gene in human osteogenic sarcomas.
Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987)


PubMed=2463881; DOI=10.1093/carcin/10.2.265
Babich M.A., Day R.S. III
Synergistic killing of virus-transformed human cells with interferon and N-methyl-N'-nitro-N-nitrosoguanidine.
Carcinogenesis 10:265-268(1989)


PubMed=2233717; DOI=10.1128/mcb.10.11.5772-5781.1990
Diller L., Kassel J., Nelson C.E., Gryka M.A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H.
p53 functions as a cell cycle control protein in osteosarcomas.
Mol. Cell. Biol. 10:5772-5781(1990)


PubMed=1385192; DOI=10.1016/0531-5565(92)90007-m
Fleming T.P., Matsui T., Aaronson S.A.
Platelet-derived growth factor (PDGF) receptor activation in cell transformation and human malignancy.
Exp. Gerontol. 27:523-532(1992)


PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4
Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N., Scheel C., Boecker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C.
Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping.
Cancer Genet. Cytogenet. 140:145-152(2003)


PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809
Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R., Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B., Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G., Gabbert H.E., Poremba C.
Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.
Cancer Res. 64:3395-3405(2004)


PubMed=15289353; DOI=10.1158/0008-5472.CAN-04-0522
Tsukahara T., Nabeta Y., Kawaguchi S., Ikeda H., Sato Y., Shimozawa K., Ida K., Asanuma H., Hirohashi Y., Torigoe T., Hiraga H., Nagoya S., Wada T., Yamashita T., Sato N.
Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor.
Cancer Res. 64:5442-5448(2004)


PubMed=17981215; DOI=10.1016/j.cancergencyto.2007.08.003
Selvarajah S., Yoshimoto M., Maire G., Paderova J., Bayani J., Squire J.A., Zielenska M.
Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization.
Cancer Genet. Cytogenet. 179:52-61(2007)


PubMed=19787792; DOI=10.1002/gcc.20717
Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.
Genes Chromosomes Cancer 49:40-51(2010)


PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)


PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)


PubMed=21519327; DOI=10.1038/labinvest.2011.72
Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M., Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.
Lab. Invest. 91:1195-1205(2011)


PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)


PubMed=23144859; DOI=10.1371/journal.pone.0048262
Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H., Cleton-Jansen A.-M., Serra M., Liestol K., Hogendoorn P.C.W., Hovig E., Myklebost O., Meza-Zepeda L.A.
Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.
PLoS ONE 7:E48262-E48262(2012)



暂无相关产品!
公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经...
联系我们 / Contact
电 话:021-56760357;021-56760351
传 真:
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved.
技术支持:中乔新舟沪ICP备14008091号